Athens Medical C.S.A. (IATR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Athens Medical C.S.A. (IATR) has a cash flow conversion efficiency ratio of 0.029x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€3.17 Million ≈ $3.71 Million USD) by net assets (€108.78 Million ≈ $127.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Athens Medical C.S.A. net asset quality index to measure how much of total assets are equity-financed.
Athens Medical C.S.A. - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Athens Medical C.S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check IATR cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Athens Medical C.S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Athens Medical C.S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kafrit
TA:KAFR
|
0.104x |
|
Namyang Dairy
KO:003920
|
0.010x |
|
TerrAscend Corp
F:TED
|
0.081x |
|
Hirequest Inc
NASDAQ:HQI
|
0.097x |
|
Biomm S.A
SA:BIOM3
|
-0.164x |
|
BioInvent International AB
ST:BINV
|
0.082x |
|
PT Satu Visi Putra Tbk
JK:VISI
|
-0.009x |
|
Centaurus Metals Ltd
AU:CTM
|
-0.097x |
Annual Cash Flow Conversion Efficiency for Athens Medical C.S.A. (2014–2024)
The table below shows the annual cash flow conversion efficiency of Athens Medical C.S.A. from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see IATR stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €108.81 Million ≈ $127.21 Million |
€46.44 Million ≈ $54.30 Million |
0.427x | +77.67% |
| 2023-12-31 | €108.77 Million ≈ $127.16 Million |
€26.13 Million ≈ $30.55 Million |
0.240x | +19904.30% |
| 2022-12-31 | €103.25 Million ≈ $120.71 Million |
€124.00K ≈ $144.97K |
0.001x | -99.22% |
| 2021-12-31 | €102.06 Million ≈ $119.32 Million |
€15.75 Million ≈ $18.41 Million |
0.154x | -66.59% |
| 2020-12-31 | €87.07 Million ≈ $101.79 Million |
€40.21 Million ≈ $47.01 Million |
0.462x | +15.96% |
| 2019-12-31 | €79.08 Million ≈ $92.46 Million |
€31.50 Million ≈ $36.82 Million |
0.398x | +42.46% |
| 2018-12-31 | €71.62 Million ≈ $83.73 Million |
€20.02 Million ≈ $23.41 Million |
0.280x | +1258.18% |
| 2017-12-31 | €63.18 Million ≈ $73.87 Million |
€-1.52 Million ≈ $-1.78 Million |
-0.024x | -114.98% |
| 2016-12-31 | €60.65 Million ≈ $70.91 Million |
€9.78 Million ≈ $11.43 Million |
0.161x | -26.39% |
| 2015-12-31 | €58.85 Million ≈ $68.80 Million |
€12.89 Million ≈ $15.07 Million |
0.219x | +350.93% |
| 2014-12-31 | €73.81 Million ≈ $86.29 Million |
€3.58 Million ≈ $4.19 Million |
0.049x | -- |
About Athens Medical C.S.A.
Athens Medical C.S.A., together with its subsidiaries, offers healthcare services in Greece and internationally. The company offers diagnosis and treatment for prostate bladder, kidney, and testicular cancer, as well as interventional cardiology, interventional electrophysiology, and pediatric cardiology; cardiac surgery; robotic surgery, including general, gynecologic, and urology services; and … Read more